Trial Profile
Prevention of Alzheimer's Disease in Women: Risks and Benefits of Hormone Therapy -Continuation of: "The Kronos Early Estrogen Prevention Study (KEEPS)"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary) ; Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Acronyms KEEPS
- 13 Jul 2023 Status changed from active, no longer recruiting to completed.
- 27 Sep 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
- 27 Sep 2022 Status changed from recruiting to active, no longer recruiting.